Innovating Works

ST. ANNA KINDERKREBSFORSCHUNG GMBH

Desconocido
Mostrando 1 al 20 de 22 resultados
ERDERA: EUROPEAN RARE DISEASES RESEARCH ALLIANCE ST. ANNA KINDERKREBSFORSCHUNG GMBH participó en un HORIZON EUROPE: HORIZON-HLTH-2023-DISEASE-07 The European Rare Diseases Research Alliance (ERDERA) aims to improve the health and well-being of the 30 million people living with a rare...
2024-08-20 - 2031-08-31 | Financiado
EngineeringSARCOMAs: Building models of fusion-driven sarcomas via cell fate engineering ST. ANNA KINDERKREBSFORSCHUNG GMBH tramitó un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 One of the unsolved problems in cancer biology is why and how do certain oncogenic driver genes promote cancer in one cellular context but n...
2024-04-25 - 2026-04-30 | Financiado
SARCOMAkids: Developmentally programmed pediatric sarcomas: a versatile platform for drug discovery and molecular... ST. ANNA KINDERKREBSFORSCHUNG GMBH tramitó un HORIZON EUROPE: ERC-2022-COG Pediatric sarcomas account for ~20% of childhood cancers. They have disappointing survival rates, with very little therapeutic progress over...
2023-09-25 - 2028-09-30 | Financiado
Maxima Butterfly: From Caterpillar to BUTTERFLY: supporting transformation of DCs in a paediatric oncology network ST. ANNA KINDERKREBSFORSCHUNG GMBH participó en un HORIZON EUROPE: HORIZON-MSCA-2021-COFUND-01 Every year, around 600 children in the Netherlands get cancer and one in four children dies from this illness. More than ten years ago, a gr...
2022-10-10 - 2027-12-31 | Financiado
B-ALLeles: High resolution dissection of non-coding determinants of disease ST. ANNA KINDERKREBSFORSCHUNG GMBH tramitó un HORIZON EUROPE: HORIZON-MSCA-2021-PF-01 While mutations at protein-coding sequences have been extensively characterized, the functional role of disease-associated non-coding varian...
2022-08-08 - 2024-10-31 | Financiado
PanCareSurPass: PanCare studies of the scale up and implementation of the digital Survivorship Passport to improve p... ST. ANNA KINDERKREBSFORSCHUNG GMBH participó en un H2020: H2020-SC1-BHC-2018-2020 Almost 500,000 former childhood cancer patients (CCS) are now living in Europe. Compared to the general population, CCS represent a vulnerab...
2021-01-21 - 2025-02-28 | Financiado
ERICA: European Rare dIsease research Coordination and support Action ST. ANNA KINDERKREBSFORSCHUNG GMBH participó en un H2020: H2020-SC1-BHC-2018-2020 Rare diseases are defined as diseases that affect not more than 1 person per 2000 in the European population. While individual rare diseases...
2021-01-15 - 2025-02-28 | Financiado
FIND-seq: Functional Interrogation of Non coding DNA Sequences in leukemia development and drug resistance ST. ANNA KINDERKREBSFORSCHUNG GMBH tramitó un H2020: ERC-2020-STG Functional non-coding regions of the genome play a fundamental role in gene expression and are enriched for disease associated variants. Per...
2020-11-09 - 2026-02-28 | Financiado
VAGABOND: Validation of Actionable Genomic ABerrations in a paediatric Oncology Network for Doctorate students ST. ANNA KINDERKREBSFORSCHUNG GMBH participó en un H2020: H2020-MSCA-ITN-2020 Pre-clinical drug development for paediatric cancers is very complex, resource intensive and requiring multi-disciplinary expertise and inno...
2020-08-18 - 2024-11-30 | Financiado
TREL: Twinning in Research and Education to improve survival in Childhood Solid Tumours in Lithuania ST. ANNA KINDERKREBSFORSCHUNG GMBH participó en un H2020: H2020-WIDESPREAD-2018-2020 Vilnius University Hospital Santaros Klinikos (VULSK) acts as a coordinator of the TREL (Twinning in Research and Education to improve survi...
2020-06-12 - 2023-12-31 | Financiado
Instand-NGS4P: Integrated and standardized NGS workflows for Personalised therapy ST. ANNA KINDERKREBSFORSCHUNG GMBH participó en un H2020: H2020-SC1-BHC-2018-2020 Instand-NGS4P is a 65-month PCP project federating 7 leading medical centers (two are coordinating ERNs) as buyers’ group with major experie...
2019-12-13 - 2025-05-31 | Financiado
iDysChart: Charting key molecules and mechanisms of human immune Dysregulation ST. ANNA KINDERKREBSFORSCHUNG GMBH tramitó un H2020: ERC-2018-COG The central challenge for the immune system is to efficiently recognize and neutralize foreign antigen while protecting self. If the latter...
2019-03-20 - 2025-05-31 | Financiado
EJP RD: European Joint Programme on Rare Diseases ST. ANNA KINDERKREBSFORSCHUNG GMBH participó en un H2020: H2020-SC1-BHC-2018-2020 As recognized by the Council Recommendation 2009/C 151/02, rare diseases (RD) are a prime example of a research area that can strongly profi...
2018-12-13 - 2024-08-31 | Financiado
CLOSER: Childhood Leukemia Overcoming distance between South America and Europe Regions ST. ANNA KINDERKREBSFORSCHUNG GMBH participó en un H2020: H2020-SC1-BHC-2018-2020 Cancer has become an important public health problem worldwide and inequalities in access to malignancies control result in differences in p...
2018-12-10 - 2024-03-31 | Financiado
PRIMAGE: PRedictive In silico Multiscale Analytics to support cancer personalized diaGnosis and prognosis Em... ST. ANNA KINDERKREBSFORSCHUNG GMBH participó en un H2020: H2020-SC1-DTH-2018-2020 PRIMAGE proposes a cloud-based platform to support decision making in the clinical management of malignant solid tumours, offering predictiv...
2018-11-14 - 2023-05-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.